UroGen Pharma Ltd. (URGN)
Valuation Overview•Is UroGen Pharma Ltd. Overvalued or Undervalued?
The market is pricing the stock in line with historical averages, assuming steady-state growth.
Fragile underlying quality score of 30/100; weak margins or elevated debt leverage warrant caution.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Highly distressed profile flashing severe fundamental warning signs.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
URGN struggles with subpar profitability and pressured margins. This is paired with a moderately leveraged but stable balance sheet.
The company is driving exceptional top-line expansion (19.5% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-77.0%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $51.0M | +21.4% | +19.5% | +56.2% | — | |
| EBITDA | -$19.6M | — | -16.6% | — | — | |
| Net Income | -$23.6M | -21.0% | -11.8% | — | -28.3% | |
| EPS (Diluted) | $-0.47 | -7.8% | — | — | +5.3% | |
| Free Cash Flow | -$45.4M | -67.7% | -22.8% | -8.7% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 89.9% | 89.2% | 89.0% | 76.9% |
| Operating Margin | -77.0% | -100.0% | -123.0% | -61698.2% |
| Net Margin | -94.8% | -134.6% | -161.0% | -59300.2% |
| FCF Margin | -118.2% | -116.1% | -132.6% | -40137.5% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.56 | $-0.47 | +16.1% | ||
| Q1'26 | $-0.52 | $-0.54 | -4.2% | ||
| Q4'25 | $-0.72 | $-0.69 | +4.2% | ||
| Q3'25 | $-0.82 | $-1.05 | -28.0% | ||
| Q2'25 | $-0.83 | $-0.92 | -10.8% | ||
| Q1'25 | $-0.69 | $-0.80 | -15.9% | ||
| Q4'24 | $-0.84 | $-0.55 | +34.5% | ||
| Q3'24 | $-0.82 | $-0.91 | -11.0% |
Total return is +125.8% (1Y), outperforming the benchmark by +100.8%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +47.8% | +38.5% | — |
| 1Y | +125.8% | +100.8% | — |
| 3YCAGR | +42.1% | +21.5% | — |
| 5YCAGR | +15.3% | +1.9% | — |
| 10YCAGR | +9.2% | -4.7% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about UroGen Pharma Ltd. (URGN) valuation, health, and returns.
UroGen Pharma Ltd. is estimated to be fairly valued under our discounted cash flow framework. trading near fair value (DCF: $0.00)
UroGen Pharma Ltd. has multiple valuation anchors: DCF Intrinsic Value: $0.00 | Wall Street Analyst Target: $42.50 (implying +26.6% upside). A convergence of these signals offers higher conviction.
UroGen Pharma Ltd. displays weak financial health with a composite quality score of 30/100, supported by a Altman Z-Score of -5.6 (distress zone), Piotroski F-Score of 1/9.
UroGen Pharma Ltd. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
UroGen Pharma Ltd.'s current growth trajectory is Stable. The company achieved +21.4% 1Y revenue growth and -7.8% 1Y EPS growth, compared to its 3Y revenue CAGR of +19.5%.
Wall Street consensus is Buy based on 15 analysts, beating EPS expectations in 42% of recent quarters with a 1-quarter streak. The consensus price target represents a +26.6% change from current levels.
Investment risks for UroGen Pharma Ltd. include: -42.2% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 1.20x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.